Development of a Cardiac Signal Analysis Algorithm for Bladder Filling Assessment: Pilot Study (ENURESIA 1)

May 19, 2026 updated by: University Hospital, Lille

The puropose of this clinical trial is to build a database of signals issued from the device to delvelop signal processing algorithms to calculat the LFVI.

This study will be carried out in the urology department of the Claude Huriez Hospital.

Electrods will be placed on the patient body to capture the ECG during the urodynmic evaluation.

The recording of the ECG will last fir the duration of the evaluation. This procedure will not affect the usual care of the patient

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France
        • CHU de Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients undergoing urodynamic testing for pure stress urinary incontinence caused by urethral hypermobility

Description

Inclusion Criteria:

  • patient undergoing urodynamic testing for pure stress urinary incontinence caused by urethral hypermobility

Exclusion Criteria:

  • Urge urinary incontinence or mixed urinary incontinence
  • Bladder emptying disorder
  • Bladder sensory disorder
  • History of pelvic surgery
  • History of perineal surgery
  • History of spinal surgery
  • Neurological condition / dysfunction
  • Subjects with an implanted medical device (pacemaker, etc.)
  • Allergy to a component of the PC-ECG 1200 device (Norav medical ®)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
low-frequency variability index
Time Frame: 15 minutes
develop an algorithm for calculating a low-frequency variability index (LFVI) that enables an effective assessment of bladder filling.
15 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2023

Primary Completion (Actual)

May 15, 2024

Study Completion (Actual)

May 15, 2024

Study Registration Dates

First Submitted

May 19, 2026

First Submitted That Met QC Criteria

May 19, 2026

First Posted (Actual)

May 26, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022_0653
  • 2022-A02836-37 (Other Identifier: ID-RCB number, ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urinary Incontinence

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe